Trial · NCT06451419
Registered outcomes135
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 135
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in non motor symptoms scale from baseline to 2 years | 2 years | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Primary | Change in non motor symptoms scale from baseline to 6 months | 6 months | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Primary | Change in non motor symptoms scale from 6 months to 1 year | 6 months | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Primary | Change in non motor symptoms scale from 12 months to 18 months | 6 months | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Primary | Change in non motor symptoms scale from 18 months to 24 months | 6 months | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Secondary | Change in Montreal Cognitive Assessment scale from baseline to 2 years | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Montreal Cognitive Assessment scale from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Montreal Cognitive Assessment scale from 6 months to 12 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Montreal Cognitive Assessment scale from12 months to 18 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Montreal Cognitive Assessment scale from18 months to 24 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Parkinson's disease cognitive rating scale from baseline to 24 months | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. |
| Secondary | Change in Parkinson's disease cognitive rating scale from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. |
| Secondary | Change in Parkinson's disease cognitive rating scale from 6 months to 12 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. |
| Secondary | Change in Parkinson's disease cognitive rating scale from 12 months to 18 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. |
| Secondary | Change in Parkinson's disease cognitive rating scale from 18 months to 24 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. |
| Secondary | Change in Line Orientation Judgement scale from baseline to 24 months | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. |
| Secondary | Change in Line Orientation Judgement scale from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. |
| Secondary | Change in Line Orientation Judgement scale from 6 months to 12 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. |
| Secondary | Change in Line Orientation Judgement scale from 12 months to 18 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. |
| Secondary | Change in Line Orientation Judgement scale from 18 months to 24 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06451419/registered